DA Davidson Reiterates Buy Rating on UCB
DA Davidson maintains its buy rating on UCB with a $40 price target.
Key Points
- DA Davidson reiterated its buy rating on UCB, setting a price target of $40 on June 15, 2026.
- UCB shares are trading at $34.63, with institutional activity showing mixed changes among major funds.
- Recent insider buying at UCB includes purchases by several executives, while analysts maintain positive outlooks.
DA Davidson has reiterated its buy rating on UCB, setting a new price target of $40. This reaffirmation came on June 15, 2026, as the stock traded at $34.63.
Other Institutional Activity in UCB
BlackRock, Inc. reduced its holdings in UCB by 90,024 shares, holding 17,861,636 shares valued at approximately $562.5 million. FMR LLC also trimmed its position by 156,450 shares, ending with 8,950,235 shares worth about $281.8 million. In contrast, Vanguard Portfolio Management LLC initiated a position with 8,044,992 shares valued at $253.3 million. Dimensional Fund Advisors LP increased its stake by 182,397 shares, bringing its total to 6,520,132 shares valued at $205.3 million. State Street Corp also boosted its holdings by 262,394 shares, totaling 6,232,961 shares worth nearly $197.8 million.
UCB Stock Snapshot
UCB shares are currently trading at $34.63. The stock has seen varied institutional activity, with some funds reducing and others increasing their positions.
Insider Buying and Selling at United Community Banks, Inc.
Recent insider activity at UCB includes a sale by Alan Kumler, SVP and Chief Accounting Officer, who sold 113 shares at an average price of $32.06 on May 15, 2026. On May 13, 2026, several insiders, including David Wilkins, Sally Pope Davis, James Clements, Jennifer Mann, and Kenneth Daniels, each acquired 2,330 shares, although the price was not disclosed.
Analysts Set New Price Targets
On June 15, 2026, DA Davidson maintained its buy rating for UCB with a $40 price target. Previously, on April 28, 2026, Stephens & Co. also maintained a buy rating with the same target. Piper Sandler kept a hold rating with a $36 target on April 22, 2026. Keefe, Bruyette & Woods upgraded UCB to a buy with a $40 target on April 9, 2026.
About UCB
UCB is a global biopharmaceutical company that focuses on discovering and developing innovative medicines and solutions for people living with severe diseases in immunology and neurology. The company operates globally, with headquarters in Brussels, Belgium.
Bottom Line
DA Davidson's reiteration of a buy rating with a $40 target reflects continued confidence in UCB's prospects. Investors often track these analyst updates as they can provide insights into the company's potential. However, it's important to remember that these ratings are opinions and not guarantees of future performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.